2,000 Shares in Hims & Hers Health, Inc. (NYSE:HIMS) Purchased by Venturi Wealth Management LLC

Venturi Wealth Management LLC purchased a new position in shares of Hims & Hers Health, Inc. (NYSE:HIMS) in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm purchased 2,000 shares of the company’s stock, valued at approximately $48,000.

A number of other institutional investors also recently modified their holdings of HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the fourth quarter valued at approximately $28,000. Raleigh Capital Management Inc. raised its position in Hims & Hers Health by 1,100.0% during the fourth quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock valued at $29,000 after purchasing an additional 1,100 shares in the last quarter. GAMMA Investing LLC lifted its stake in Hims & Hers Health by 2,173.7% during the fourth quarter. GAMMA Investing LLC now owns 2,251 shares of the company’s stock worth $54,000 after purchasing an additional 2,152 shares during the last quarter. Principal Securities Inc. boosted its holdings in shares of Hims & Hers Health by 48.2% in the 4th quarter. Principal Securities Inc. now owns 3,079 shares of the company’s stock valued at $74,000 after purchasing an additional 1,002 shares in the last quarter. Finally, Quest Partners LLC increased its stake in shares of Hims & Hers Health by 22.6% in the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after purchasing an additional 807 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Trading Down 22.1 %

Shares of HIMS stock opened at $39.95 on Wednesday. Hims & Hers Health, Inc. has a 1-year low of $9.67 and a 1-year high of $72.98. The stock has a market cap of $8.73 billion, a price-to-earnings ratio of 90.79 and a beta of 1.35. The stock has a 50-day moving average of $35.62 and a 200-day moving average of $26.25.

Hims & Hers Health (NYSE:HIMS) last released its earnings results on Monday, February 24th. The company reported $0.11 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.02. The business had revenue of $481.14 million during the quarter, compared to the consensus estimate of $494.56 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. Sell-side analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 268,932 shares of the firm’s stock in a transaction that occurred on Monday, January 6th. The stock was sold at an average price of $27.75, for a total transaction of $7,462,863.00. Following the completion of the sale, the insider now owns 169,803 shares of the company’s stock, valued at $4,712,033.25. This trade represents a 61.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Michael Chi sold 2,054 shares of Hims & Hers Health stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. The trade was a 1.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 1,097,578 shares of company stock worth $38,080,320 over the last three months. 17.71% of the stock is owned by company insiders.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the company. Piper Sandler raised their price objective on Hims & Hers Health from $24.00 to $35.00 and gave the company a “neutral” rating in a research note on Tuesday. Morgan Stanley downgraded shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $42.00 to $60.00 in a research note on Tuesday, February 18th. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Leerink Partners increased their price objective on shares of Hims & Hers Health from $24.00 to $40.00 and gave the company a “market perform” rating in a research note on Tuesday. Finally, Canaccord Genuity Group boosted their target price on shares of Hims & Hers Health from $38.00 to $68.00 and gave the stock a “buy” rating in a research note on Wednesday, February 19th. Two analysts have rated the stock with a sell rating, eight have assigned a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat, Hims & Hers Health currently has an average rating of “Hold” and a consensus price target of $33.40.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.